The European Medicines Agency (EMA) is continuing its mission as best it can, despite the departure of 125 of its employees with Brexit on the horizon. This is essentially the message adopted by its Management Board at its meeting on 12 and 13 June.
The Management Board validated the Agency's 2018 activity report, assessed the state of preparedness of the pharmaceutical industry for Brexit, reviewed the development of a European register containing information related to clinical trials...